Anna Snook


I enjoy working with clients for the full life cycle of the company, from formation to exit and everything in between.

Anna Snook focuses her practice on advising private companies on a wide range of corporate matters, including formation, financings, mergers and acquisitions, and general corporate governance matters. Anna also advises public companies on public and private offerings of equity, SEC reporting obligations, and general corporate governance matters.

In addition to her daily practice, Anna co-leads the firm’s Women Associates Group, which serves as a safe space for discussion of issues affecting women in and outside of the firm, promotes advancement of women and networking in the firm, and facilitates discussions of current events affecting women professionals.


  • Boston College Law School, cum laude, 2018
  • Boston College, magna cum laude, 2014

Bar and Court Admissions

  • Massachusetts



  • Kula Bio, a leader in sustainable nitrogen solutions, in a $50 million Series A financing and a $10 million Series Seed financing
  • Pear Therapeutics, Inc., a pioneer of prescription digital therapeutics, in connection with its $80 million Series D Financing led by SoftBank Vision Fund 2 
  • 7AC Technologies, a developer of ultra-high efficiency HVAC systems, in its sale to Emerson Electric
  • Glympse Bio, a biotechnology company advancing the way diseases are understood, tracked and treated, in its $46.7 million Series B financing
  • Energetic Insurance, a Managing General Underwriter (MGU), in its initial $2.5 million Series Seed financing
  • Honest Buildings, a real estate project management platform in its sale to Procore Technologies, a leading provider of construction management software
  • Pika Energy, a manufacturer of innovative battery storage technologies, in its sale to power products manufacturer Generac Holdings
  • Tank Utility, a provider of IoT tank monitoring and logistics optimization services, in a financing round led by Bullpen Capital
  • CredSimple, an NCQA certified credentialing and provider data management solution, in its acquisition of Glenridge Health, a technology-enabled provider network management solutions company


  • Pear Therapeutics, Inc. (Nasdaq: PEAR), a pioneer of prescription digital therapeutics, in a SPAC IPO/reverse merger of Pear Therapeutics, Inc. with and into a wholly owned subsidiary of Thimble Point Aquisition Corp. (THMA), with Pear Therapeutics, Inc. surviving the merger and THMA changing its name to Pear Therapeutics, Inc.
  • Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), a multi-state cannabis operator, in closing an underwritten public offering of approximately US$228 million of subordinate voting shares
  • Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company, in:
    • its $64.7 million underwritten public offering of Class A common stock
    • its $50.3 million underwritten public offering of Class A common stock

Speaking Engagements

  • Speaker, “Equity Compensation Basics for Startups,” Greentown Labs (October 30, 2019)